Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized blue) and tagged with antibodies (colorized yellow) against the virus’ fusion protein — the target of RSV ...

The RSVpreF vaccine demonstrated 91% effectiveness against RSV-related lower respiratory tract disease in older adults during ...

Figure 1: The potential pool of patients who may seek respiratory syncytial virus (RSV) treatments. Figure 2: Shifting market composition of respiratory syncytial virus (RSV) agents.

Respiratory syncytial virus (RSV) is a major cause of respiratory infections, particularly in infants, children under 5 years, and older adults. Its rapid spread makes RSV a serious public health ...